Research progress on the treatment improvement of HPV-associated oropharyngeal cancer.
10.13201/j.issn.2096-7993.2023.09.010
- Author:
Shuqi ZHAO
1
;
Zhengxue HAN
1
Author Information
1. Department of Oral and Maxillofacial-Head and Neck Oncology，Capital Medical University School of Stomatology，Beijing，100050，China.
- Publication Type:Journal Article
- Keywords:
human papillomavirus（HPV）;
oropharyngeal cancer;
reducing treatment intensity
- MeSH:
Humans;
Papillomavirus Infections;
Oropharyngeal Neoplasms/therapy*;
Risk Factors
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2023;37(9):740-747
- CountryChina
- Language:Chinese
-
Abstract:
The number of new cases of oropharyngeal cancer is increasing year by year among the world, and HPV infection is one of the risk factors for this malignant tumor. Compared with HPV-negative oropharyngeal cancer, HPV-positive patients are more sensitive to radiotherapy and have a better prognosis, but there is no accepted treatment for HPV-positive patients. Reducing treatment intensity moderately and exploring the best option to minimize side effects of treatment are urgent issues to be addressed. This article reviews the research progress on the treatment improvement of HPV-associated oropharyngeal cancer in recent years.
